Based on the immunomodulatory effect in the clinical trial enrolled lymphoma patients, this study aims to explore the potential of the first in class highly selective ITK inhibitor soquelitinib in enhancing the persistence and antitumor functionality of CAR-T cells. The gene discussed is ITK; the disease is lymphoma.